ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): The Annual General Meeting of ALK-Abelló A/S will be held on Thursday 18 March 2021 at 4.00pm (CET) as a fully electronic Annual General Meeting. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached.
Shareholders who have registered their attendance can participate in the Annual General Meeting via VP’s VGM portal. The Annual General Meeting will also be webcast live at ALK’s website: https://ir.alk.net/agm.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,400 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Wolters Kluwer N.V.19.9.2025 08:00:00 CEST | Press release
Wolters Kluwer completes capital reduction
Orion Oyj19.9.2025 08:00:00 CEST | Press release
80,802 Orion Corporation A shares converted into B shares
JDE Peet's N.V.19.9.2025 07:55:00 CEST | Press release
Update on intended recommended public offer by KDP for JDE Peet's
Sampo plc19.9.2025 07:30:00 CEST | Press release
Sampo plc’s share buybacks 18 September 2025
Idorsia Pharmaceuticals Ltd19.9.2025 07:00:00 CEST | Press release
Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom